COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A5BT
|
|||
| Drug Name |
Camostat mesylate
|
|||
| Synonyms |
Camostat (mesylate); Camostat Methanesulfonate; Camostat methanesulfate; DSSTox_CID_238; DSSTox_GSID_20238; DSSTox_RID_75452; FOY 305; FOY-305; FOY305; Foipan; Foipan (TN); Foipan mesylate; NCGC00167526-01; Q-200778; UNII-451M50A1EQ; camostat mesilate; 451M50A1EQ; C21H26N4O8S; CAS-59721-29-8; CHEMBL85164
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) | Phase 2 | [1], [2] | Middle East Respiratory Syndrome (MERS) | Investigative | [3] | Severe acute respiratory syndrome (SARS) | Investigative | [3] |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H26N4O8S
|
|||
| Canonical SMILES |
CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N.CS(=O)(=O)O
|
|||
| InChI |
1S/C20H22N4O5.CH4O3S/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22;1-5(2,3)4/h3-10H,11-12H2,1-2H3,(H4,21,22,23);1H3,(H,2,3,4)
|
|||
| InChIKey |
FSEKIHNIDBATFG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 59721-29-8
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:31347
|
|||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN transmembrane protease serine 2 (TMPRSS2) | Target Info | Inhibitor | [1], [3] |
| Camostat mesylate inhibits MERS-CoV, SARS-CoV and SARS-CoV-2 in vitro via inhibiting TMPRSS2 which is a serine protease that mediates the cell surface entry pathway. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. | |||
| 2 | ClinicalTrials.gov (NCT04353284) Camostat Mesylate in COVID-19 Outpatients | |||
| 3 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.